Floatz logo

Recombinant Human Hyaluronidase

Richter Syndrome

SWOG Cancer Research NetworkPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

56 Active assets in the Richter Syndrome cohort.

Asset / SponsorPhaseRating
Obinutuzumab
Christine Ryan
Phase 2BB
Venetoclax
Northwestern University
Phase 2BB
Ibrutinib
City of Hope Medical Center
Phase 2BB
Pirtobrutinib
SWOG Cancer Research Network
Phase 3BB
Cyclophosphamide
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Recombinant Human Hyaluronidase is also rated in:

follicular lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
nodular lymphocyte predominant Hodgkin lymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →